Table 2. Osteopontin and survival in individual cancers.
| Cancer | Concordance | P-value | Studies |
|---|---|---|---|
| Lung | 1.000 | 0.001 | 3 |
| Breast | 0.917 | 0.004 | 8 |
| Prostate | 1.000 | 0.013 | 3 |
| Head and neck | 1.000 | 0.020 | 4 |
| Liver | 0.875 | 0.033 | 8 |
| Cervical | 1.000 | 0.126 | 3 |
| Esophageal | 1.000 | 0.126 | 3 |
| Gastric | 0.750 | 0.189 | 3 |
| Kidney | 1.000 | 0.249 | 2 |
| Mesothelioma | 1.000 | 0.249 | 2 |
Published curves for overall survival were digitised for analysis. P-values in bold are considered significant. They indicate that Osteopontin over-expression is associated with elevated risk for death from cancer. For several cancer types, only one published study was available. Those cases were excluded from the meta-analysis. Shown are only cancers for which more than one published study was available for evaluation.